Rallis India FY26 Revenue Rises 9% to ₹2,897 Cr; EBITDA Surges 26% to ₹362 Cr
Rallis India reported FY26 revenue up 9% to ₹2,897 crore and record EBITDA of ₹362 crore, a 26% increase. Q4FY26 revenue rose 6% to ₹456 crore, with EBITDA improving significantly. FY26 PAT grew 47% to ₹184 crore. Crop Care and Seeds segments showed strong growth.
The announcement details strong financial results, including record EBITDA and substantial growth in revenue and profit, which are material to investors and the company's valuation.
The company reported record EBITDA and significant year-on-year growth in revenue and profit for the full financial year and the fourth quarter, indicating a positive financial performance.
Rallis India Limited announced its financial results for the quarter and financial year ended March 31, 2026, presenting an investor presentation on April 27, 2026.
The company reported a resilient performance in a challenging environment, driven by broad-based volume growth and cost optimization. For FY26, revenue increased by 9% to ₹2,897 crore from ₹2,663 crore in FY25. EBITDA for FY26 reached a record high of ₹362 crore, a significant increase of 26% from ₹287 crore in FY25.
In the fourth quarter of FY26 (Q4FY26), revenue grew by 6% to ₹456 crore from ₹430 crore in Q4FY25. Q4FY26 EBITDA saw a substantial increase of 96%, moving from a loss of ₹19 crore in Q4FY25 to a loss of ₹1 crore in Q4FY26. Profit After Tax (PAT) for FY26 increased by 47% to ₹184 crore from ₹125 crore in FY25. Q4FY26 PAT also improved significantly, rising by 52% from a loss of ₹32 crore in Q4FY25 to a loss of ₹15 crore in Q4FY26.
The Crop Care segment demonstrated strong performance, with Q4FY26 revenue increasing by 5% YoY, driven by volume growth. Specifically, Crop Protection B2C revenue rose by 15% YoY, and Soil & Plant Health (SPH) revenue grew by 27% YoY. However, Q4FY26 B2B revenue, including CSM, declined by 8% YoY. For FY26, Crop Care EBITDA increased by 17% to ₹292 crore, and PAT rose by 34% to ₹151 crore.
The Seeds business also showed robust growth, with Q4FY26 revenue up by 23% YoY due to both volume and price increases. FY26 revenue for Seeds grew by 15% to ₹481 crore. FY26 EBITDA for the Seeds segment surged by 87% to ₹69 crore, and PAT increased by 167% to ₹33 crore.
Despite industry challenges such as adverse weather conditions, crop shifts, and lower pest pressure, Rallis India launched 11 new products in FY26, including 7 Herbicides, 2 Fungicides, and 2 Insecticides. The Seeds business launched 19 new products. The company highlighted its integrated value chain, strong distribution network, and customer-centric digital interventions as key strengths.
What to do with a filing like this
Rallis India Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Rallis India Limited. Read the original for the full detail.